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Codon bias imposes a targetable limitation on
KRAS-driven therapeutic resistance
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KRAS mutations drive resistance to targeted therapies, including EGFR inhibitors in colorectal
cancer (CRC). Through genetic screens, we unexpectedly find that mutant HRAS, which is
rarely found in CRC, is a stronger driver of resistance than mutant KRAS. This difference is
ascribed to common codon bias in HRAS, which leads to much higher protein expression, and
implies that the inherent poor expression of KRAS due to rare codons must be surmounted
during drug resistance. In agreement, we demonstrate that primary resistance to cetuximab is
dependent upon both KRAS mutational status and protein expression level, and acquired
resistance is often associated with KRASQ61 mutations that function even when protein
expression is low. Finally, cancer cells upregulate translation to facilitate KRASG12-driven
acquired resistance, resulting in hypersensitivity to translational inhibitors. These findings
demonstrate that codon bias plays a critical role in KRAS-driven resistance and provide a
rationale for targeting translation to overcome resistance.
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P
rimary and acquired resistance to targeted therapies place
major limitations on the clinical efficacy of these drugs,
despite their promising preclinical potential1. One proposed
method to overcome resistance has been to identify genetic2,
epigenetic and signalling alterations that underlie sensitivity and
resistance, and then use these as biomarkers to better select
patients that will benefit from specific mono- or combination
therapies3–5. In this regard, numerous studies have specifically
implicated activating mutations in KRAS as a major driver of both
primary and acquired resistance to diverse targeted therapies.
In the area of primary resistance, activating mutations in KRAS
track with poor responses to EGFR inhibition with the
monoclonal antibodies (mAbs) cetuximab and panitumumab,
or small molecule EGFR inhibitors like gefitinib and erlotinib, in
colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
patients6–10. Activating mutations in KRAS have also been
proposed as a mechanism of primary resistance to the tyrosine
kinase inhibitor (TKI) imatinib in KIT- or PDGFRA-mutant
gastrointestinal stromal tumours11 and to JAK inhibitors in
JAK2-mutant myeloproliferative neoplasms12.
In addition to cases of primary resistance, the emergence of
de novo KRAS mutations has also been linked to acquired
resistance in multiple cancer types and contexts: to both
anti-EGFR therapy and MEK1/2 inhibitors in CRC13,14, to
imatinib in chronic myelogenous leukaemia15, and to BRAF/
MEK inhibitors in melanoma16. In CRC, despite achieving initial
responses, patients who originally present with no detectable
mutations in KRAS (wild-type (WT) KRAS, or KRASWT, disease)
develop acquired resistance to anti-EGFR therapy that is
commonly driven by KRAS mutations, limiting the clinical
benefit of this therapy13,17–19. Curiously, the mutations detected
in this setting of acquired resistance are a balance of G12/G13 and
Q61 mutations, the latter of which are rarely found in treatment
naive CRC20,21. An improved understanding of the biology and
signalling that support KRAS-mediated resistance may therefore
give rise to new therapeutic strategies for these refractory
tumours.
KRAS belongs to a family of three genes, the other two being
HRAS and NRAS. Interestingly, it is KRAS that is the most
commonly mutated of the three in a wide spectrum of cancers
and in the setting of resistance22. Despite this apparent contrast
in epidemiological data, the encoded proteins are very similar,
and in fact share B85% sequence identity22. However, we
discovered that the coding nucleotide sequence varies extensively
between these three genes. Specifically, HRAS is enriched in
common codons that yield robust translation and hence high
protein expression. KRAS is characterized by rare codons,
yielding poor translation and low expression, while NRAS has a
mixture of common and rare codons and intermediate
expression22.
Here, we show that this rare-codon bias, entrenched in the
nucleotide sequence of KRAS, plays a critical role in both primary
and acquired resistance and may underlie observations of elevated
KRAS expression in models of resistance to the mAb cetuximab,
the emergence of more rare KRAS amino acid site mutations in
patients with acquired cetuximab resistance, and provide a novel
therapeutic avenue to combat resistance.
Results
MutantHRAS confers greater drug resistance than mutant KRAS.
Previously, we described a systematic approach to identify novel
drug resistance pathways by screening cancer cell lines with a
pooled library of 36 mutant complementary DNAs (cDNAs) that
constitutively activate or inhibit 17 key oncogenic signalling
pathways23. Using this approach, we observed that across nine
genotype- and lineage-defined groupings of 14 cell lines, treated
with a total of 14 targeted therapies, there was a marked
differential resistance conferring potential between oncogenic
HRASG12V and KRASG12V (Fig. 1a). Specifically, oncogenic
HRASG12V conferred resistance in 27 of 29 screens with a broad
spectrum of therapeutics using a previously established scoring
threshold (Fig. 1b)23, and it scored as the top overall hit in 22 of
29 of the screens (Fig. 1c). By contrast, KRASG12V scored only
rarely (6 of 29 screens), and never as the top overall hit.
Moreover, even in screens where both HRASG12V and KRASG12V
reached scoring criteria, HRASG12V consistently achieved
higher enrichment scores (the relative abundance of each
construct in the presence of drug normalized to the same value in
the absence of drug), implying stronger resistance (Fig. 1d).
To determine whether the ability to score in our screens
correlated with the expression of each construct, we performed
western blot analysis using extracts from cell lines in which both
constructs (A375) or only HRASG12V (SKBR3, PC9, NCIH508)
scored. In all cases examined, HRASG12V was detected at higher
levels compared to KRASG12V (Fig. 1e). Thus, the level of RAS
expression correlated with resistance, with HRAS consistently
expressed at higher levels.
Codon bias underlies increased resistance conferred by HRAS.
One feature of RAS genes that could explain the enhanced
resistance conferred by HRAS relative to KRAS is codon bias.
To address this hypothesis, we created native-codon and
codon-modified cDNAs encoding FLAG-tagged, oncogenic
HRAS and KRAS. Specifically, we created a rare codon-enriched,
oncogenic HRASG12D cDNA by converting key common codons
to rare codons (termed HRASR,G12D). Reciprocally, we also
created a common codon-enriched, oncogenic KRASG12D cDNA
by exchanging rare codons for common codons (termed
KRASC,G12D). These four constructs as well as an empty vector
control were individually stably expressed in three very different
human cancer cell lines, namely the BRAFV600E mutation-positive
melanoma cell line UACC-62 (Fig. 2a–c), the EGFR
mutation-positive NSCLC cell line PC9 (Fig. 2d–f), and the
PDGFR-amplified NSCLC cell line NCIH1703 (Fig. 2g–i). In
agreement with the known effect of codon bias on RAS protein
expression22, oncogenic HRASG12D was readily detected by
immunoblot analysis, and its expression was greatly reduced
following the exchange of common codons for rare codons in all
three cell lines (Fig. 2a,d,g). Conversely, oncogenic KRASG12D
was very poorly expressed in all three cell lines, an effect that was
reversed by changing rare codons to common (Fig. 2a,d,g). When
these cell lines were treated with targeted inhibitors against the
driver oncogene in each line, namely vemurafenib to inhibit
oncogenic BRAF in UACC-62 cells, gefitinib to inhibit oncogenic
EGFR in PC9 cells and sunitinib to inhibit PDGFR in NCIH1703
cells, we found that in each case the degree of resistance matched
RAS protein expression. Namely, the RAS isoforms with the most
common codons (HRASG12D and KRASC,G12D) imparted greater
resistance than the versions with more rare codons (HRASR,G12D
and KRASG12D) (Fig. 2b,e,h, quantified in Fig. 2c,f,i). The
same was also true in the completely independent assay of
anchorage-independent growth (Supplementary Fig. 1). Thus, the
ability of oncogenic HRAS to impart resistance to a broad
spectrum of cell lines and drugs appears to be due, at least in part,
to its high-level protein expression due to its inherent bias
towards common codons.
Codon bias underlies KRAS-mediated resistance to cetuximab.
The aforementioned finding appears, at face value, at odds with
the clinical observation that oncogenic KRAS has been extensively
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implicated as a driver of primary and acquired resistance. We
posited that perhaps poor expression of KRAS due to rare codons
is a barrier to resistance, such that in addition to an oncogenic
mutation, resistance may require an increase in KRAS expression.
To this end we focused on CRC, a cancer in which oncogenic
KRAS is well established to be a central driver of primary and
acquired resistance to anti-EGFR therapies13. The CRC cell line
NCIH508, which is KRASWT, sensitive to the drug cetuximab,
and can be rendered resistant to cetuximab through expression of
oncogenic RAS, was stably transduced with the aforementioned
vectors encoding no transgene or HRASG12D, HRASR,G12D,
KRASG12D or KRASC,G12D. As before, expression of the RAS
isoforms tracked with codon bias (Fig. 3a). Further, we observed
that common codon-enriched RAS constructs conferred
resistance to cetuximab in colony growth assays relative to rare
codon-enriched RAS constructs (Fig. 3b,c). Identical findings
were observed upon treatment of cells with an eight-log dilution
series of cetuximab, where half-maximal growth inhibition values
for both HRASG12D and KRASC,G12D were significantly greater
than for their rare codon-enriched counterparts (Fig. 3d,e). These
results were reproducible in another KRASWT CRC cell line,
LIM1215 (Supplementary Fig. 2A,B). Immunoblots performed in
the presence and absence of cetuximab in cells expressing
controls or common and rare RAS constructs demonstrated
on-target inhibition of the mitogen-activated protein kinase
(MAPK) pathway, as evidenced by modest to substantial
decreases in phospho-ERK (p-ERK) levels in both NCIH508
and LIM1215 cell lines (Fig. 3f, Supplementary Fig. 2C). This
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effect on MAPK signalling correlated with the degree of cell
death, specifically quantification of the extra long-BIM splice
variant (EL-BIM) as well as total BIM levels (T-BIM), where
decreased induction of this pro-apoptotic protein was observed in
common codon-expressing cells when treated with cetuximab, an
effect that was lost in the same cells expressing the rare codon
counterparts (Fig. 3g, Supplementary Fig. 2D). Furthermore,
Annexin V staining revealed that treatment with cetuximab led to
significant increases in Annexin V-positive cells in control and
rare-codon RAS-expressing cells, and that this induction was
reduced in cells expressing HRASG12D and KRASC,G12D (Fig. 3h,
Supplementary Fig. 2E). Collectively, these results demonstrate
that codon bias underlies the isoform-specific effects of
RAS-driven resistance to cetuximab in CRC cell lines, and that
common codon-expressing RAS isoforms drive resistance, at least
partially through the suppression of drug-induced apoptosis. This
finding suggests that overcoming poor translation of oncogenic
KRAS may promote greater resistance to EGFR inhibitors.
Clinical model reveals selection of potent KRASmutations. The
demonstration that codon bias limits KRAS-driven therapeutic
resistance in CRC suggests several testable, clinically relevant
hypotheses. For example, low levels of KRAS expression may
select for more potent activating mutations that drive acquired
resistance without fully overcoming suppressed protein synthesis.
Recent work has established that although mutations in KRAS
codons 12, 13 and 61 are all oncogenic, codon 61 mutations
directly disrupt GTPase activity and more potently activate KRAS
than allosteric codon 12 and 13 activating mutations24,25.
Consistent with this idea, although it has been well established
that activating mutations in codons 12, 13 and 61 of KRAS are
all considered drivers of acquired resistance to anti-EGFR mAbs
in metastatic CRC patients17,20,26, there appears to be an
unexplained preponderance of codon 61 mutations in patients
with anti-EGFR refractory disease, mutations which are seldom
observed in patients prior to the initiation of therapy21,27.
We therefore hypothesized that this detection of Q61 site
mutations in tumours with acquired resistance may reflect a
selection for more potent mutations to overcome the inherent
poor translation of KRAS. Indeed, by analysing three separate
cohorts of metastatic CRC patients with acquired resistance to
anti-EGFR therapy27–30, we found that in all three groups, and in
one combined subset of the groups, there was a significant
enrichment in the number of KRASQ61 site mutations in
comparison to a treatment naive background population
(Table 1). We next modelled two different point mutations in
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Figure 2 | Codon bias underlies the differential resistance conferred by oncogenic HRAS versus KRAS. (a,d,g) Immunoblot analysis with anti-FLAG and
anti-b-actin in extracts from indicated cell lines stably transduced with a vector encoding the indicated transgene (or no transgene, empty). All HRAS and
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codons 12 or 61 of KRAS in the aforementioned KRASWT CRC
cell lines (NCIH508 and LIM1215), then calculated the
sensitivities of these lines to cetuximab. KRASQ61 site mutations
were stronger drivers of resistance to anti-EGFR therapy than
oncogenic KRASG12 site mutations (Fig. 4a,b, Supplementary
Fig. 3A,B). Similar to our findings with rare and common
codon-enriched RAS constructs, we observed on-target activity of
cetuximab in these cells, as evidenced by reduced p-ERK levels
(Fig. 4c, Supplementary Fig. 3C) and induction of EL-BIM and
T-BIM that was suppressed by the resistance-conferring KRASQ61
mutations (Fig. 4d, Supplementary Fig. 3D). Importantly, these
effects were independent of KRAS protein expression levels,
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which were similarly low across the various 12 and 61 point
mutations tested (Fig. 4e, Supplementary Fig. 3E). Together, these
data suggest that selection for stronger KRAS mutations can
overcome poor KRAS expression imposed by codon bias, a result
that may explain the enrichment of KRASQ61 site mutations in
patients with acquired cetuximab resistance.
KRAS expression determines intrinsic resistance to cetuximab.
Aside from the possibility of selection for a more potent
oncogenic mutation, another potential mechanism to overcome
the inability of oncogenic KRAS to potently impart drug
resistance is by producing more of the protein. As such, primary
KRAS-driven resistance to cetuximab may be dependent not only
on the presence of activating mutations, as is commonly
understood17, but also on the degree to which cells surmount
poor KRAS expression prior to therapy. To test this hypothesis,
we examined a panel of 21 KRASG12/G13 mutant CRC cell lines
that were previously characterized for their intrinsic sensitivity to
cetuximab31 to determine whether the degree of resistance to this
drug correlated with the expression level of mutant KRAS
protein. Indeed, after stratifying cell lines on the basis of
responsiveness to cell growth inhibition in the presence of
cetuximab (with responsive lines being defined as exhibiting
410% growth inhibition by cetuximab and non-responsive lines
showing no growth inhibition), we found a significant elevation
in KRAS expression in non-responsive cell lines relative to
responsive lines (Fig. 5a,b). We then compared global translation
rates in cetuximab responsive and non-responsive cell lines by
labelling with the translation elongation inhibitor puromycin,
which leads to direct puromycin incorporation into nascent
polypeptides that can be detected with anti-puromycin
antibodies32. Following 15min of puromycin treatment,
immunoblotting revealed the rate of global translation to be
higher in cetuximab non-responsive cell lines than cetuximab
responsive cell lines, and quantification of labelling showed a
significant correlation with KRAS expression in these cell lines
(Supplementary Fig. 4A,B). This observed correlation between
intrinsic resistance, KRAS protein expression and global
protein synthesis suggests that KRAS mutational status alone
may not fully predict primary resistance to EGFR inhibition
in CRC. Instead, the expression level of mutant KRAS is likely
to be a second key contributor to resistance, a notion that
directly implicates codon bias and the ability of cancer cells to
adopt mechanisms that overcome the translational barrier it
imposes.
To begin discerning what cellular programs might be involved
in upregulating mutant KRAS protein expression, we analysed a
broader panel of KRAS-mutant lung, pancreatic and CRC cell
lines, and observed that lines that displayed high endogenous
KRAS protein expression (KRAS-high lines) also tended to
exhibit elevated expression of an ectopic KRAS transgene when
compared to cell lines with low endogenous KRAS protein
expression (KRAS-low lines) (Fig. 5c). This was unexpected, as
KRAS cDNAs are typically expressed poorly in the absence of
codon optimization (refer to Fig. 1), suggesting the intriguing
possibility of a mechanism(s) in these cells to overcome poor
KRAS expression that is transferable to a plasmid-borne KRAS
cDNA. To investigate whether this feature reflects a more general
strategy by cancer cells dependent on mutant KRAS expression to
overcome poor oncogene translation, we next stably expressed an
AKT3 cDNA, which is similarly enriched in rare codons and
poorly expressed22, in this panel of KRAS mutant cell lines.
Interestingly, many KRAS-high lines also displayed elevated levels
of AKT3 when compared to their KRAS-low counterparts
(Fig. 5d, Supplementary Fig. 4C). By contrast, we did not
observe a correlation between expression levels of ectopic KRAS
and ectopic NRAS, the latter of which contains approximately
equal percentages of rare and common codons (Supplementary
Fig. 4D,E). To further test this concept, we stably expressed the
gene pair ORMDL3/1, which is analogous to HRAS/KRAS in that
it exhibits divergent codon bias and protein expression22, in
KRAS-high/low cells. Divergent codon-dependent expression of
ORMDL1/3 was completely normalized in the KRAS-high cell
line SW900, even in the absence of codon optimization of the rare
codon-enriched ORMDL1, but was not observed in the
KRAS-low cell line AsPC1 (Fig. 5e). Finally, to compare global
translation in these KRAS-high/low lines, a time course of
puromycin labelling was used, revealing the rate of global
translation to be higher in KRAS-high cells (SW900) than
KRAS-low cell cells (AsPC1) (Fig. 5f). Collectively, these data
suggest that cancer cells can overcome poor KRAS expression by
globally upregulating protein synthesis through mechanisms that
also enable cancer cells to overcome the effects of codon bias.
Selective targeting of anti-EGFR resistant colorectal cancer.
The above results suggest the intriguing possibility that tumours
with acquired KRASG12 or KRASG13 site mutations must
overcome poor translation to achieve resistance. To test this
hypothesis, we measured the levels of KRAS protein in the
parental LIM1215 cell line and in two independently derived,
KRASG12/G13 mutant clones selected for resistance to
cetuximab13. In both clones, KRAS protein levels were higher
than the parental cells (Fig. 6a–c). The same result was observed
when the experiment was repeated using the cell line OXCO2
(Supplementary Fig. 5A,B). Consistent with our previous
observations, upregulated KRAS expression in resistant
derivatives was associated with increased global translation rate
(Supplementary Fig. 5C). Upregulation of global translation is
sufficient to increase KRAS protein expression levels, as ectopic
expression of eIF4E, a key factor in protein synthesis, drove
increases in KRAS expression in parental LIM1215 cells to levels
comparable to those observed in a resistant derivative
(Supplementary Fig. 5D). (We note that, as expected,
eIF4E-driven upregulation of KRASWT expression was
insufficient to drive resistance to cetuximab, as resistance also
requires mutational activation of KRAS (Supplementary Fig. 5E).)
Given the evidence that cells overcome KRAS codon bias
by upregulating translation (Fig. 5), we hypothesized that
inhibitors of translation may be selectively potent in CRC
cells with acquired KRASG12 or KRASG13 site mutations, thereby
revealing a synthetic lethality of the resistant state and a
potential target in anti-EGFR resistant disease. We selected a
Table 1 | KRAS mutational status prevalence among
treatment naive and treatment resistant cohorts.
KRAS
mutation
No.
(patients)
Total P value
Treatment naive28 G12/13 76 224
Q61 4 224
Treatment resistant29 G12/13 20 24 0.0108
Q61 10 24 o0.0001
Treatment resistant30 G12/13 3 16 0.42
Q61 8 16 o0.0001
Treatment resistant27 G12/13 NA NA o0.0001
Q61 9 27
Treatment
resistant29,30
G12/13 23 40 0.0864
Q61 18 40 o0.0001
P values as assessed by two-tailed Fisher’s test. NA, not applicable. Superscripts signify
reference number.
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panel of translational inhibitors, including Rapamycin
(an allosteric mTORC1 inhibitor), AZD2014 and MLN0128
(ATP- competitive mTORC1/2 inhibitors), BEZ235 (a dual
ATP-competitive mTOR/PI3K inhibitor), and 4EGI-1
(a direct eIF4E inhibitor), and found that in all cases, acquired-
resistant derivatives were significantly more sensitive to these
inhibitors. For the case of allosteric and ATP-competitive mTOR
inhibitors in particular, many of which are FDA approved or in
advanced clinical development, we observed growth inhibition of
resistant clones at doses 10- to 100-fold lower than their matched
parental counterparts (Fig. 6d). Further, levels of KRAS protein
were diminished in resistant cells when compared to parental
cells within 4 h of treatment with each translational inhibitor
(Fig. 6e). KRAS is differentially required for the growth of
resistant cells relative to their parental counterparts as evidenced
by short hairpin RNA (shRNA) knockdown experiments
(Supplementary Fig. 5F,G). As such, the enhanced growth
inhibitory effects of translational inhibitors in resistant cells
parallels the effects of KRAS knockdown. Together, these data
suggest that in CRC cells with KRASG12/G13 mutation-driven
acquired resistance, a translationally primed state overcomes
codon bias and facilitates expression of mutant KRAS at levels
sufficient to potentiate resistance. Thus, the targeting of this
translation-dependent state may provide a novel, selective
therapeutic target for the treatment of anti-EGFR refractory
disease.
Discussion
Despite providing a clinically significant survival benefit to patients
with metastatic KRAS WT CRC, acquired resistance to the anti-
EGFR mAbs cetuximab and panitumumab can arise via three
predominant mechanisms: (1) genetic alterations involving down-
stream EGFR effectors, including KRAS, (2) activation of parallel
receptor tyrosine kinase pathways, including HER2 and c-MET and
(3) mutations in the extracellular domain of EGFR33. KRAS
mutations appear to be the most common driver of acquired
resistance to anti-EGFR mAbs. In one study, serial sampling of
patient sera revealed that 9 out of 24 (38%) patients with initially
KRAS WT tumours developed detectable mutations in KRAS
between 5 and 6 months after the initiation of panitumumab
monotherapy34. In another study, analysis of metastases from
patients who developed resistance to anti-EGFR mAbs showed the
emergence of KRAS amplification in one sample and acquisition of
secondary KRAS mutations in 60% (6 out of 10) of the cases
examined13. Although KRAS has been shown to play a central role
in primary and acquired resistance to anti-EGFR therapy in CRC as
well as in other therapeutic contexts, no effective pharmacological
inhibitors of KRAS, or other RAS oncoproteins, have reached the
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clinic to date35. This stands in contrast with the other predominant
mechanisms of anti-EGFR resistance. For example, alternative
receptor tyrosine kinase pathways such as HER2 and c-MET can be
targeted with selective TKIs36. Similarly, extracellular domain
mutations in EGFR, which occur in about 20% of CRC patients
treated with anti-EGFR mAbs33, can be treated with oligoclonal
antibodies like MM-151 and Sym004, which have been shown to
overcome this resistance mechanism in model systems and are now
being explored clinically as secondary therapies for patients who
have relapsed on anti-EGFR mAbs33,37,38. Thus, there is a
particularly compelling need for therapeutic strategies that block
KRAS-driven resistance to EGFR inhibitors in CRC.
Our findings suggest that the resistance-conferring ability of
mutant KRAS is limited by codon bias, a mechanism that controls
the expression and subsequent downstream activities of RAS
proteins. Indeed, cells with acquired cetuximab resistance driven
by canonical KRASG12/G13 site mutations exhibit higher levels of
this protein. Alternatively, the selection for more potent KRAS
mutations is an alternative mechanism to overcome codon bias, a
concept that may explain the paradoxical enrichment of KRASQ61
mutations observed in patients with anti-EGFR refractory disease.
Combined, these studies suggest that KRAS-mediated therapeutic
resistance may require higher levels of KRAS activity than
KRAS-mediated tumorigenesis, an idea that is consistent with
other signal amplification-based resistance mechanisms39. To
examine these concepts further, future studies to determine the
direct relationship between KRAS expression levels in patient
tumours and subsequent clinical response to anti-EGFR mAbs are
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warranted. Similarly, direct comparison of KRAS expression
levels before and following the onset of KRASG12-mediated
acquired resistance will shed further light on the universality of
translational upregulation in this context.
Previously, it has been demonstrated that oncogenic activation
of translation initiation and/or elongation can support
tumorigenesis by driving selective upregulation of specific mRNA
transcripts40. Indeed, seminal studies revealed that
overexpression of eIF4E, involved in the translation initiation
complex of protein synthesis, was sufficient to drive
tumorigenesis in cell lines and spontaneous tumorigenesis in
mice41–43. In addition, deregulation of translation has more
recently been identified as both a primary downstream
consequence of oncogenic signalling, as well as a central
mediator of resistance to clinical therapies, including drugs
targeting the MAPK and PI(3)K-AKT-mTOR signal transduction
pathways44,45. These findings, along with data showing that
cancer cells co-opt translational machinery to support tumour
growth, have driven increased interest in targeting translational
control as a method to selectively kill cancer cells46.
By treating cells with direct and/or indirect inhibitors of
protein synthesis, it is possible to selectively target the
translationally primed state that facilitates KRASG12/G13-mediated
acquired resistance. Although our studies indicate that these
resistant cells exhibit hypersensitivity to diverse inhibitors of
translation, future studies are required to determine the reason
for this sensitivity and the specific mechanisms imparting greater
translation of KRAS, which may lead to more precise and refined
approaches to target these tumours. Importantly, however,
indirect inhibitors of translation such as rapamycin and
MLN0128, and their analogues, are already in clinical
development. As such, studies to examine the sensitivity of
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patients with KRASG12/G13-mediated resistance to these agents, or
the ability of upfront treatment with these agents in combination
with anti-EGFR mAbs to shape resistance evolution, are
warranted.
Methods
Cell lines and reagents. All cell lines were grown at 37 C in 5% CO2. A375, PC9,
NCIH508, UACC-62, H1073, LIM1215, SW620, SW480, SW900, HPAFII,
Capan-2, AsPC-1, SU.86.86, CFPAC1, H727, H358, OXCO2 and LoVo were
cultured in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin.
SKBR3 was cultured in McCoy’s 5a supplemented with 10% FBS and 1%
penicillin/streptomycin. All other cell lines were purchased from American Type
Culture Collection (ATCC) or Duke University Cell Culture Facility (CCF).
LIM1215, OXCO2 and matched anti-EGFR resistant derivatives, as well as KRAS
mutant CRC lines and cetuximab, were used as previously described18. All other
drugs were purchased from Selleck Chemicals, ChemieTek, MedChemExpress,
Ontario Chemicals, Sigma-Aldrich, or Apex Bio.
Colony formation and soft agar growth assays. For colony formation assays,
UACC-62, PC-9, H1073 and NCI-H508 cells selected for stable expression of the
indicated RAS constructs were seeded in duplicate into six-well plates at 250 cells
per well. Twenty-four hours later, DMSO or the indicated drug (in DMSO)
were added to cells. DMSO or drug-containing media was replaced every 2 days
and the assays were cultured for 14–21 days. Plates were then rinsed with
phosphate-buffered saline (PBS), fixed in 10% formalin for 5min and stained with
0.1% crystal violet stain for 30min. Plates were rinsed in distilled water and
scanned. ImageJ software was used to quantify colony growth area as a percentage
of the well covered. Anchorage-independent growth was assayed in six-well plates
with 1ml of 0.6% bactoagar media solution (final concentration 1 DMEM, 10%
FBS, 1 penicillin/streptomycin) as a bottom support layer. A total of 4 104
UACC-62 cells selected for stable expression of indicated RAS constructs were
resuspended in RPMI (10% FBS, 1 penicillin/streptomycin) and mixed 1:1 with
0.6% bactoagar media solution to give a final bactoagar concentration of 0.3%,
0.2 mM vemurafenib (or equivalent amount DMSO). Cells were then plated in
triplicate to give final density of 1 104 cells per well. Each well was fed with fresh
media and drug on days 7 and 14. Colonies were counted on day 21.
Short-term growth-inhibition assay (GI50). Cells were seeded into 96-well
plates at 1,000 cells per well for inhibition assays to cetuximab or at 5,000 cells per
well for all other drugs tested. To generate GI50 curves, cells were treated with
vehicle (PBS or DMSO) or an eight-log serial dilution of drug. Each treatment
condition was represented by at least three replicates. Seven days after cetuximab
addition or 3 days after all other drug additions, cell viability was measured using
Cell Titer Glo (Promega). Relative viability was then calculated by normalizing
luminescence values for each treatment condition to control treated wells. To
generate GI50 curves for exogenously expressed KRAS experiments, slight
modifications were made. Cells were seeded at 300,000 cells per well in six-well
plates. The following day cells were infected with the desired retroviral constructs.
Following 2 days of puromycin selection (2mgml 1), the cells were seeded into
96-well plates at 5,000 cells per well. Dose–response curves were fit using
GraphPad/Prism 6 software.
Western blotting and antibodies. Immunoblotting was performed as previously
described47, and membranes were probed with the following primary antibodies at
the corresponding dilutions: vinculin, b-actin, BIM, p-ERK1/2, ERK, p-AKT
(S473,T308), AKT, eIF4E at 1:1,000 (Cell Signaling); HRAS, NRAS and KRAS at
1:100 (Santa Cruz Biotechnology); FLAG at 1:1,000 (M2; Sigma Aldrich); Myc at
1:1,000 (Invitrogen) and Puromycin at 1:10,000 (Millipore). To determine
correlation between ectKRAS and ectAKT3 protein levels, immunoblots were
scanned and quantified using ImageJ software. For each cell line analysed, the band
density of ectKRAS and ectAKT3 (relative to actin) was determined and plotted
graphically. For quantification of EL-BIM, T-BIM and KRAS protein levels,
immunoblots were scanned, quantified using ImageJ software, and the band
density of each protein (relative to vinculin) was determined and plotted
graphically.
Pathway activating screens. Data are excerpted from screens previously
reported12,18,23.
Puromycin incorporation. Cell lines were cultured to B70% confluence were
treated with DMSO or 5 mM puromycin for the indicated time periods. After
incubation, cells were washed with PBS to halt puromycin incorporation. Cells
were lysed and subjected to immunoblotting with anti-puromycin antibody
(Millipore, 1:10,000).
Lentiviral and retroviral production and infection of cells. Experiments
performed using HRAS, KRAS and NRAS point mutants and codon-modified
constructs were conducted as previously described22,48. Lentiviral experiments
were performed as previously described23,49. In brief, HEK293T cells were
transfected with a mixture of VSVG, PsPAX2, the construct of interest, and
Opti-MEM and FuGENE 6 Transfection Reagent. The following day, transfection
media was replaced with 20ml of harvest media (RPMIþ 30% FBSþ 1% PS)
collected at 48 h post media change. Collected virus was passed through a 0.45 mM
filter and frozen at  80 C prior to use in infection of various cell lines. We note
here that the ability to successfully ectopically express oncogenic RAS was variable
from cell line to cell line.
shRNA constructs. TRC shRNA clones (Table 2) were obtained from the Duke
RNAi Facility as glycerol stocks. Constructs were prepared in lentiviral form and
used to infect target cells, as previously described50.
Quantification of apoptosis by Annexin-V. Cells were seeded in 12-well plates
and treated the next day with no agent, cetuximab (34.3 10 8M) or vehicle
(PBS). Cells were incubated for 5 days and then washed twice with ice-cold PBS,
and resuspended in 1 Annexin V binding buffer (10mM HEPES, 140mM NaCl,
2.5mM CaCl2; BD Biosciences). Surface exposure of phosphatidylserine was
measured using APC-conjugated Annexin V (BD Biosciences). 7-AAD (BD
Biosciences) was used as a viability probe. Experiments were analysed at 20,000
counts per sample using BD FACSVantage SE. Gatings were defined using
untreated/unstained cells as appropriate.
Statistics. Results are expressed as the means±s.e.m. Unless otherwise specified,
for comparisons between two groups, P values were calculated with unpaired, two-
tailed Student’s t-tests.
Data availability. All data generated or analysed during this study are included in
this published article (and its Supplementary Information files).
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